Patogenia do Sars-cov-2 no Sangue e Utilização de Plasma Convaslescente Como Estratégia de Tratamento: Uma Revisão de Literatura

Abstract

In 2020 the world was surprised by the emergence of a new coronavirus, SARS- CoV-2. Belonging to the same lineage as the already known SARS-CoV and

MERS-CoV, it has spread across the world causing a significant number of deaths and overloading health systems. Among the main complications observed in critically ill patients are coagulopathies, which are imbalances in blood coagulation mechanisms. In this context, in addition to the need for vaccines, there was also a demand for the development of treatment strategies for those infected, especially those severely affected. One of these strategies is the use of convalescent plasma, which is plasma rich in antibodies from an individual who has recovered from the disease. Despite the advance of vaccination in the population, the use of convalescent plasma can be an alternative way to fight the disease. This strategy could be used not only for Sars-Cov-2, but also for other viral diseases while vaccines or other more efficient mechanisms are not yet available.